Nantahala Capital Management LLC Acquires 47,589 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Nantahala Capital Management LLC grew its holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 3.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,452,153 shares of the company’s stock after acquiring an additional 47,589 shares during the period. Nantahala Capital Management LLC owned 2.12% of Amylyx Pharmaceuticals worth $5,489,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Connor Clark & Lunn Investment Management Ltd. grew its position in Amylyx Pharmaceuticals by 43.4% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,263,353 shares of the company’s stock worth $4,775,000 after acquiring an additional 382,608 shares in the last quarter. Geode Capital Management LLC grew its position in Amylyx Pharmaceuticals by 3.1% in the fourth quarter. Geode Capital Management LLC now owns 567,903 shares of the company’s stock worth $2,148,000 after acquiring an additional 16,864 shares in the last quarter. Renaissance Technologies LLC grew its position in Amylyx Pharmaceuticals by 70.9% in the fourth quarter. Renaissance Technologies LLC now owns 464,400 shares of the company’s stock worth $1,755,000 after acquiring an additional 192,600 shares in the last quarter. Wellington Management Group LLP bought a new stake in Amylyx Pharmaceuticals in the fourth quarter worth approximately $793,000. Finally, Federated Hermes Inc. grew its position in Amylyx Pharmaceuticals by 8.6% in the fourth quarter. Federated Hermes Inc. now owns 202,316 shares of the company’s stock worth $765,000 after acquiring an additional 16,030 shares in the last quarter. 95.84% of the stock is owned by institutional investors.

Insider Buying and Selling at Amylyx Pharmaceuticals

In other news, insider Camille L. Bedrosian sold 12,425 shares of Amylyx Pharmaceuticals stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $3.47, for a total transaction of $43,114.75. Following the sale, the insider now directly owns 194,375 shares in the company, valued at approximately $674,481.25. The trade was a 6.01 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bernhardt G. Zeiher purchased 10,000 shares of the company’s stock in a transaction that occurred on Thursday, March 20th. The stock was acquired at an average cost of $3.70 per share, with a total value of $37,000.00. Following the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $37,000. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 64,509 shares of company stock valued at $222,586 in the last ninety days. Company insiders own 11.70% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Mizuho raised shares of Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $3.00 to $7.00 in a report on Monday, April 7th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Amylyx Pharmaceuticals in a report on Wednesday, March 5th. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Amylyx Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $8.00.

Amylyx Pharmaceuticals Price Performance

Shares of Amylyx Pharmaceuticals stock opened at $5.36 on Monday. Amylyx Pharmaceuticals, Inc. has a fifty-two week low of $1.58 and a fifty-two week high of $7.27. The firm has a fifty day moving average price of $3.70 and a two-hundred day moving average price of $4.17. The company has a market cap of $474.91 million, a PE ratio of -1.40 and a beta of -0.53.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.06). The business had revenue of ($0.67) million for the quarter. Analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current fiscal year.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.